EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Progressive Supranuclear Palsy—A Global Review

Prashanth Lingappa Kukkle iD, Rosy Neupane, Alexandar Pantelyat iD, Anne-Marie Wills iD, Ed Jabbari iD, Elise G P Dopper iD, Gabor G Kovacs iD, Gunther Hoglinger iD, Ikuko Aiba, Irene Litvan iD, Jacky Ganguly iD, Jennifer L Whitwell iD und 9 weitere

Movement Disorders Clinical Practice · 2026-03 · 13 (3) · 611-622

DOI: 10.1002/mdc3.70338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 03.09.2025. Verfasst von Prashanth Lingappa Kukkle und 20 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease and Movement Disorders Clinic, Bangalore, India. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progressive Supranuclear Palsy (PSP) is a rare and severe neurodegenerative tauopathy characterized by diverse clinical phenotypes, including Richardson's syndrome (PSP‐RS), PSP‐parkinsonism (PSP‐P), PSP‐progressive gait freezing (PSP‐PGF), and PSP‐corticobasal syndrome (PSP‐CBS). Significant geographic variation exists in prevalence, clinical presentations, and prognosis.

Objectives

This global review aims to systematically evaluate the epidemiological variation, clinical phenotypes, diagnostic practices, and management strategies for PSP, focusing on regional disparities and identifying influencing genetic and environmental factors. Methodology A comprehensive literature search following PRISMA guidelines was conducted, analyzing studies reporting PSP epidemiology, phenotypes, diagnostic criteria, risk factors, treatments, and prognoses. Data were categorized into epidemiology, risk factors, clinical presentations, diagnosis, treatment accessibility, and outcomes, considering geographic variation.

Results

Global PSP prevalence ranges between 5–6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure. Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction. Prognosis significantly varies with subtype; PSP‐RS shows rapid progression and shorter survival (5–7 years), whereas PSP‐P has a milder clinical course (8–12 years). Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services. Diagnostic accuracy has improved with the adoption of MDS‐PSP criteria, facilitating recognition of diverse phenotypes.

Conclusions

Regional disparities in PSP prevalence, phenotypic presentation, and healthcare accessibility underscore the importance of standardized diagnostic criteria, targeted genetic and environmental studies, and equitable healthcare strategies. Enhanced global collaboration is essential for improving PSP diagnosis, management, and patient outcomes worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Supranuclear Palsy, ProgressiveHumansPrevalenceRisk Factors

Stichwörter der Autor:innen

PSP study groupclinical profileglobal comparisonprogressive supranuclear palsy

Autor:innen und Institutionen

  • Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.
  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • UCL Queen Square Institute of Neurology, London, UK.
  • Department of Neurology and Alzheimer Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Prashanth Lingappa Kukkle, Alexandar Pantelyat, Anne-Marie Wills, Ed Jabbari, Elise G P Dopper, Gabor G Kovacs, Gunther Hoglinger, Irene Litvan, Jacky Ganguly, Jennifer L Whitwell, Jinghong Ma, Ryuji Skakibara, Yared Zenebe Zewde, Huw R Morris

Zitieren

APA

Kukkle, P. L., Neupane, R., Pantelyat, A., Wills, A. M., Jabbari, E., Dopper, E. G. P., Kovacs, G. G., Hoglinger, G., Aiba, I., Litvan, I., Ganguly, J., Whitwell, J. L., Ma, J., Okeng'O, K., Skakibara, R., Forrest, S., Lorenzl, S., Zewde, Y. Z., Compta, Y., …, & MDS‐PSP Study Group (2026). Progressive Supranuclear Palsy—A Global Review. Movement Disorders Clinical Practice, 13(3), 611-622. https://doi.org/10.1002/mdc3.70338

Vancouver

Kukkle PL, Neupane R, Pantelyat A, Wills AM, Jabbari E, Dopper EGP, et al. Progressive Supranuclear Palsy—A Global Review. Movement Disorders Clinical Practice. 2026;13(3):611-622. doi:10.1002/mdc3.70338

BibTeX
@article{Kukkle2026,
  author = {Kukkle, Prashanth Lingappa and Neupane, Rosy and Pantelyat, Alexandar and Wills, Anne-Marie and Jabbari, Ed and Dopper, Elise G P and Kovacs, Gabor G and Hoglinger, Gunther and Aiba, Ikuko and Litvan, Irene and Ganguly, Jacky and Whitwell, Jennifer L and Ma, Jinghong and Okeng'O, Kigocha and Skakibara, Ryuji and Forrest, Shelley and Lorenzl, Stefan and Zewde, Yared Zenebe and Compta, Yaroslau and Morris, Huw R and MDS‐PSP Study Group, MDS‐PSP Study Group},
  title = {Progressive Supranuclear Palsy—A Global Review},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {3},
  pages = {611--622},
  doi = {10.1002/mdc3.70338}
}
Kostenlos starten →